ClinicalTrials.gg
CompletedNCT02850484Updated Aug 1, 2016

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

A Phase 1 interventional study of Budesonide and Formoterol in Asthma and Chronic Obstructive Pulmonary Disease (COPD), sponsored by Intech Biopharm Ltd.. Completed. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-01.

Sponsored by Intech Biopharm Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
62nd of 108
99 · median 124
Started
2016
with 5 others
Phase 1
10 of 110
none open now
Registered
87th of 110
by date
Lead sponsor
3 of 110
Intech Biopharm Ltd.

Among the 110 studies testing budesonide in Asthma, this one is the 62nd largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2016, is one of 10 in phase 1, and was the 87th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The objective of this pivotal study is to evaluate the relative bioavailability of SYN010 HFA Inhaler and Symbicort 160/4.5μg in healthy volunteers with charcoal block.

Read the detailed description

A pivotal, single-dose, randomized, open-label, partial replicate, three-period, three-sequence, two-treatment, three-way crossover, comparative bioavailability study.

Ninety-nine, male and female volunteers, 20-45 years of age, with a body mass index (BMI) within 18.5-30.0 kg/m2, inclusive, will be enrolled. (The body weight should be over 50 kg, inclusive, respectively)

A single dose of 8 puffs (equivalent to budesonide 1280 μg/formoterol fumarate dihydrate 36 μg) in each study period.

03

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female volunteers, aged 20-45, inclusive.
  2. that is within 18.5-30.0 kg/m², inclusive. (The body weight should be over 50 kg, inclusive, respectively)
  3. Healthy or Non Clinical Significant, according to the medical history, Electrocardiography (), Chest X-ray and physical examination as determined by the Principal Investigator/Sub-Investigator.
  4. Systolic blood pressure between 90-139 mmHg, inclusive, and diastolic blood pressure between 50-90 mmHg, inclusive, and pulse rate between 50-100 bpm, inclusive and temperature between 35.0-37.4°C.
  5. Clinical laboratory values within reference range or Non-Clinical Significance (NCS) judged by the Principal Investigator/Sub-Investigator.
  6. Ability to comprehend and be informed of the nature of the study. Capable of giving written prior to receiving any study medication. Must be able to communicate effectively with clinic staff.
  7. Ability to fast for at least 14 hours and to consume standard meals.
  8. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.
  9. Agree not to have a tattoo or body piercing until the end of the study.
  10. Female subjects must fulfill at least one of the following:

    • Be surgically sterile for a minimum of 6 months;
    • for a minimum of 1 year;
    • Agree to avoid pregnancy and use medically acceptable method of from screening day until 30 days after study has ended (last study procedure).

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of any hepatic (e.g. active liver disease, hepatic impairment), renal/genitourinary (e.g. renal impairment), gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine (e.g. hypothyroidism), immunological, musculoskeletal (e.g. myopathy, rhabdomyolysis), neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the Principal Investigator/Sub-Investigator.
  2. Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to first drug administration, as determined by the Principal Investigator/Sub- Investigator.
  3. Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the Principal Investigator/Sub-Investigator.
  4. Presence of any significant physical or organ abnormality as determined by the Principal Investigator/Sub-Investigator.
  5. A positive test result for any of the following: (HIV), surface antigen, , drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, tetrahydrocannabinol), breath alcohol test. Positive pregnancy test for female subjects.
  6. Known history or presence of:

    • Alcohol abuse or dependence within one year prior to first drug administration;
    • Drug abuse or dependence;
    • or idiosyncratic reaction to budesonide, formoterol fumarate dihydrate , its , and/or related substances;
    • Food allergies and/or presence of any dietary restrictions;
    • Severe allergic reactions (e.g. anaphylactic reactions, angioedema).
  7. Intolerance to and/or difficulty with blood sampling through venipuncture.
  8. Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets etc.
  9. Individuals who have donated, in the days prior to first drug administration:

    • Less than 250 mL of blood in the previous 60 days
    • 300 mL or more in the previous 90 days
  10. Donation of plasma by plasmapheresis within 7 days prior to first drug administration.
  11. Individuals who have participated in another clinical trial and received an drug within 30 days prior to first drug administration.
  12. Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing and containing grapefruit and/or pomelo within 10 days prior to first drug administration.
  13. Use of any prescription medication within 30 days prior to first drug administration.
  14. Use of any over-the-counter medications (including oral multivitamins, herbal and/or dietary supplements) within 30 days prior to first drug administration (except for spermicidal/barrier products).
  15. Females taking oral or transdermal hormonal contraceptives within 30 days prior to first drug administration.
  16. Females having used implanted, injected, intravaginal, or intrauterine hormonal contraceptive within 6 months prior to first drug administration.
  17. Individuals having undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by Principal Investigator/Sub-Investigator.
  18. Known history of smoking or using tobacco products, nicotine products (patches, gum etc.) within 6 months prior to first drug administration.
  19. Pregnant/lactating women.
  20. Subjects will be given training to ensure that subjects are able to correctly use the investigational products in screening. The subjects who are unable to operate the investigational products proficiently will not be included in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Active comparator
    Reference 1 Symbicort Inhaler 160/4.5μg

    Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs

    Drug: Budesonide · Drug: Formoterol

  • Experimental
    SYN010 HFA Inhaler

    SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs

    Drug: Budesonide · Drug: Formoterol

  • Active comparator
    Reference 2 Symbicort Inhaler 160/4.5μg

    Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs

    Drug: Budesonide · Drug: Formoterol

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under Curve (AUC)

    Time frame: Pre-dose and at 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 and 36 hours after dosing.

  2. Maximum plasma concentration (Cmax)

    Time frame: Pre-dose and at 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 and 36 hours after dosing.

Secondary outcomes

  1. Time to reach Maximum plasma concentration (Tmax)

    Time frame: Pre-dose and at 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 and 36 hours after dosing.

  2. Blood pressure (BP)

    Time frame: Pre-dose and at 0.5, 16, 24 and 36 hours after dosing.

  3. Body temperature (BT)

    Time frame: Pre-dose and at 0.5, 16, 24 and 36 hours after dosing.

  4. Pulse rate (PR)

    Time frame: Pre-dose and at 0.5, 16, 24 and 36 hours after dosing.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Aug 1, 2016
Start
Mar 2016
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Aug 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02850484
Lead sponsor
Intech Biopharm Ltd.
Responsible party
Sponsor
First posted
Aug 1, 2016
Start date
Mar 2016
Primary completion
May 2016
Completion
May 2016
Last update
Aug 1, 2016

Study contacts

Wen K Chang, M.D.
principal investigator · Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion